Omeprazol Medreg (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Medreg, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑esophageal reflux disease, peptic ulcer disease and erosive esophagitis. GNH USA supplies Omeprazol Medreg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Medreg is a proton pump inhibitor that acts on the gastric acid secretion pathway. - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of the esophageal lining. - Peptic ulcer disease: accelerates ulcer healing and reduces the risk of recurrence. - Erosive esophagitis: heals erosive lesions and helps prevent relapse.

Omeprazol Medreg may cause adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of unease and urge to vomit. - Diarrhoea: loose, watery stools occurring more frequently than normal.

Serious or Rare Side Effects: - Severe allergic reactions: including anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. - Clostridioides difficile infection: severe colitis associated with antibiotic‑related dysbiosis. - Electrolyte disturbances: low magnesium, vitamin B12 deficiency, or increased risk of bone fractures.

Before initiating therapy with Omeprazol Medreg, certain precautions should be observed. - Assess renal and hepatic function: adjust use if impairment is present. - Use cautiously in the elderly: monitor for increased sensitivity to side effects. - Monitor magnesium levels: prolonged use may lead to hypomagnesemia. - Avoid abrupt discontinuation: tapering may reduce rebound acid hypersecretion. - Review concomitant medications: assess for potential interactions. - Store at room temperature: keep in the original pack, protect from moisture.

Omeprazol Medreg can affect the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Atazanavir, nelfinavir, rilpivirine: reduced antiviral efficacy. - Clopidogrel: decreased conversion to active metabolite, lowering antiplatelet effect. - Methotrexate: increased systemic exposure and toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring closer monitoring. - Digoxin: potential increase in serum concentration. - HIV protease inhibitors: may require dose adjustment of either agent.